{"id":"sonazoid","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"1-5%","effect":"Allergic reactions"},{"rate":"null","effect":"Kidney problems"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by accumulating in liver cells and causing them to produce a signal that can be detected by MRI, allowing for better visualization of liver lesions. This is particularly useful for diagnosing and monitoring liver cancer and other liver conditions.","oneSentence":"Sonazoid is a liver-specific contrast agent that enhances the visibility of liver lesions during MRI.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:22.664Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Liver cancer diagnosis and monitoring"},{"name":"Liver lesion detection"}]},"trialDetails":[{"nctId":"NCT06639828","phase":"PHASE4","title":"Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging","status":"RECRUITING","sponsor":"GE Healthcare","startDate":"2025-01-20","conditions":"Focal Liver Lesions","enrollment":50},{"nctId":"NCT03335566","phase":"PHASE3","title":"An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2014-05-11","conditions":"Liver Lesions","enrollment":424},{"nctId":"NCT03340870","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetics of Sonazoid™ Following Intravenous Bolus Injection in Healthy Volunteers","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2014-10-20","conditions":"Healthy","enrollment":16},{"nctId":"NCT00822991","phase":"NA","title":"Sonazoid Enhanced Liver Cancer Trial for Early Detection","status":"UNKNOWN","sponsor":"Kindai University","startDate":"2009-01","conditions":"Hepatocellular Carcinoma, Liver Cirrhosis, Hepatitis B","enrollment":760}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":526,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["perfluorobutane","NC100100","Perfluorobutane","Contrast ultrasound microvascular perfusion imaging"],"phase":"phase_3","status":"active","brandName":"Sonazoid™","genericName":"Sonazoid™","companyName":"GE Healthcare","companyId":"ge-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sonazoid is a liver-specific contrast agent that enhances the visibility of liver lesions during MRI. Used for Liver cancer diagnosis and monitoring, Liver lesion detection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}